Pressor responses to antihypertensive drug types

American Journal of Hypertension

Volumn 23, Issue 9, 2010, Pages 1031-1037

  Alderman, Michael H ^a   Cohen, Hillel W ^a   Sealey, Jean E ^b   Laragh, John H ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

anti hypertensive drugs; blood pressure; hypertension; pressor responses; renin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN; RETROSPECTIVE STUDIES;

EID: 77955982902     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2010.114     Document Type: Article

References (24)

1. Ménard J, Serrurier D, Bautier P, Plouin PF, Corvol P. Crossover design to test antihypertensive drugs with self-recorded blood pressure. Hypertension 1988; 11:153-159.
2. Bidiville J, Nussberger J, Waeber G, Porchet M, Waeber B, Brunner HR. Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension 1988; 11:166-173.
3. Laragh JH. Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles. Am J Med 1973; 55: 261-274.
4. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension: Lesson XV. Volume-vasoconstriction equation that supports all normotension or hypertension. Am J Hypertens 2001; 14:397-404.
5. Roman MJ, Alderman MH, Pickering TG, Pini R, Keating JO, Sealey JE, Devereux RB. Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass,and vascular hypertrophy. Am J Hypertens 1998; 11:387-396.
6. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324:1098-1104.
7. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17:1-7.
8. The 1980 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1980; 140:1280-1285.
9. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension: Lesson XVI: How to choose the correct drug treatment for each hypertensive patient using a plasma renin-based method with the volume-vasoconstriction analysis. Am J Hypertens 2001; 14:491-503.
10. Longworth DL, Drayer JI, Weber MA, Laragh JH. Divergent blood pressure responses during short-term sodium restriction in hypertension. Clin Pharmacol Ther 1980; 27:544-546.
11. Egan BM, Weder AB, Petrin J, Hoffman RG. Neurohumoral and metabolic effects of short-term dietary NaCl restriction in men. Relationship to salt-sensitivity status. Am J Hypertens 1991; 4:416-421.
12. Baer L, Parra-Carrilo JZ, Radichevich I, Williams GS. Detection of renovascular hypertension with angiotensin II blockade. Ann Intern Med 1977; 86:257-260.
13. Dimsdale JE, Ziegler M, Mills P, Berry C. Prediction of salt sensitivity. Am J Hypertens 1990; 3:429-435.
14. Brown JJ, Düsterdieck G, Fraser R, Lever AF, Robertson JI, Tree M, Weir RJ. Hypertension and chronic renal failure. Br Med Bull 1971; 27:128-135.
15. Alderman MH, Lamport B. Moderate sodium restriction. Do the benefits justify the hazards? Am J Hypertens 1990; 3:499-504.
16. Drayer JI, Keim HJ, Weber MA, Case DB, Laragh JH. Unexpected pressor responses to propranolol in essential hypertension. An interaction between renin, aldosterone and sympathetic activity. Am J Med 1976; 60:897-903.
17. Blumenfeld JD, Laragh JH. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998; 11:894-896.
18. Egan BM, Basile JN, Rehman SU, Davis PB, Grob CH 3rd, Riehle JF, Walters CA, Lackland DT, Merali C, Sealey JE, Laragh JH. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens 2009; 22: 792-801.
19. Canzanello VJ, Baranco-Pryor E, Rahbari-Oskoui F, Schwartz GL, Boerwinkle E, Turner ST, Chapman AB. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension.Am J Hypertens 2008; 21:61-66.
20. Minami J, Ishimitsu T, Matsuoka H. Pretreatment plasma renin activity levels correlate with the blood pressure response to telmisartan in essential hypertension. Am J Hypertens 2008; 21:10-13.
21. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am J Hypertens 2009; 22:112-121.
22. Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high-and low-baseline PRA levels, respectively. Am J Hypertens 2009; 22:954-957.
23. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med 1993; 328:914-921.
24. Deary AJ, Schumann AL, Murfet H, Haydock SF, Foo RS, Brown MJ. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens 2002; 20:771-777.